Testing treatments on CTNNB1 patient cells plays a crucial role in assessing the efficacy of therapeutic interventions, a fundamental step in the development of precise treatments for CTNNB1 syndrome. The gene discussed is CTNNB1; the disease is severe intellectual disability-progressive spastic diplegia syndrome.